|
Headlines
Market news and breaking stories live from Dow Jones Newswires
Market Commentary
A technical analysis commentary of the major markets, only from INO
Smart Scan
A premium service, alerting you to changes in the market by web and email.
Extreme Futures / Stocks
Extreme Markets from all exchanges, updated throughout the trading day.
|
| |
|
Trade Triangle Technology, Advanced Charts, SmartScan, Trading Workshops.
The premier online video learning platform for traders.
Daily Portfolio Scan and Analysis
|
| |
|
Covidien adds kidney risk to Optimark label11 days ago
(AP:NEW YORK) Drug and medical device maker Covidien PLC said Monday it is changing the label on its imaging agent Optimark to show that the product could be dangerous to patients with severe kidney problems.
Covidien said the new label will indicate that Optimark should not be used in patients who have severe acute or chronic renal insufficiency, in patients who have kidney failure due to cirrhosis of the liver, or in patients who are about to have or are recovering from a liver transplant.
The Irish company said those patients make up less than 0.5 percent of the U.S. population combined.
Covidien said it submitted the label change to the Food and Drug Administration and is implementing it immediately. The changes will be made in all countries where Optimark is approved.
In morning trading, Covidien shares rose 56 cents to $44.61.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Back to News Index
|
